DAX25.067 -0,2%Est506.270 -0,2%MSCI World4.343 -0,1%Top 10 Crypto8,1900 +2,0%Nas26.282 +0,3%Bitcoin56.230 +0,2%Euro1,1415 ±0,0%Öl76,01 +0,1%Gold4.111 -0,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 SpaceX A42D4F NVIDIA 918422 Volkswagen (VW) vz. 766403 Deutsche Telekom 555750 Infineon 623100 SAP 716460 Bayer BAY001 Siemens Energy ENER6Y Lufthansa 823212 Micron Technology 869020 Allianz 840400 TKMS thyssenkrupp Marine Systems TKMS00 Deutsche Bank 514000 DEUTZ 630500
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Iran-Krieg im Blick: DAX geht schwächer ins Wochenende -- US-Börsen in Grün -- VW: Modellpalette soll schrumpfen -- SK hynix, SpaceX, Tesla, Meta, Bayer, Siemens Energy, DEUTZ, Plug Power im Fokus
Top News
NVIDIA-Aktie im Blick: Der KI-Riese erobert den nächsten Milliardenmarkt NVIDIA-Aktie im Blick: Der KI-Riese erobert den nächsten Milliardenmarkt
Diesel-Rechtsstreit in Großbritannien: Entlastung für die Mercedes-Benz-Aktie nach Gerichtsurteil? Diesel-Rechtsstreit in Großbritannien: Entlastung für die Mercedes-Benz-Aktie nach Gerichtsurteil?
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Insmed Aktie

Kaufen
Verkaufen
Insmed Aktien-Sparplan
101,22 EUR -2,46 EUR -2,37 %
BMN
115,60 USD +0,04 USD +0,03 %
nachbörslich
BTT
finanzen.net zero
Insmed jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.22,46 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1JJA3

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS4576693075

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolINSM

Insmed Aktien News

DatumMeistgelesen
PR NewswireInsmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
PR NewswireInsmed To Present at the 44th Annual J.P. Morgan Healthcare Conference
Wer­bungInsmed-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
PR NewswireInsmed Provides Clinical and Business Update
PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireEuropean Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
PR NewswireEuropean Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
PR NewswireInsmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good
PR NewswireInsmed To Present at November and December 2025 Investor Conferences
PR NewswireInsmed Reports Third-Quarter 2025 Financial Results and Provides Business Update
PR NewswireInsmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List
PR NewswireCHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
PR NewswireInsmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025
PR NewswireInsmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025
PR NewswireInsmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025
PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireBloomberg 500 (B500) Index Adds Sixteen Securities Following Semi-Annual Reconstitution
PR NewswireInsmed To Present at September Investor Conferences
PR NewswireFDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
PR NewswireInsmed Reports Second-Quarter 2025 Financial Results and Provides Business Update
PR NewswireInsmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025
PR NewswireInsmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension
PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireInsmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference
PR NewswireBrensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study
PR NewswireInsmed Reports First-Quarter 2025 Financial Results and Provides Business Update
PR NewswireInsmed To Present at the BofA Securities 2025 Health Care Conference
PR NewswireNew England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
PR NewswireInsmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025
PR NewswireInsmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference
PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireInsmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis
PR NewswireInsmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update
PR NewswireInsmed To Present at March 2025 Investor Conferences
PR NewswireInsmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025
PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireFDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025
PR NewswireInsmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed News

Insmed News: auf dieser Seite finden Sie alle Insmed News und Nachrichten zur Insmed Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Insmed News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Insmed News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.